Several years ago, Heather was given three doses of psilocybin as part of a clinical study for treatment-resistant depression. Ever since, she’s been experiencing strange visual distortions. What's happening to her? Listen to Altered States podcasts.apple.com/gb/podcast/the…

And some of that pressure is coming from the conventions of a regulatory system that doesn’t know what to do with a paradigmatically challenging approach (ie drug + therapy). Squeeze that round peg into a square hole? Or time to better test & consider the different paradigm?

Coming very soon: Music For Mushrooms - Official Documentary Trailer youtu.be/8zC-FwDBdBQ?si… via YouTube

Within-subject comparison of near-death and psychedelic experiences: acute and enduring effects dlvr.it/TCjMwr

It’s high time the field of psychedelic research move beyond the mystical experience construct (MEQ). While many critiques of the measure rest on misconceptions, persistent misunderstandings & psychometric limitations lead us to recommend transcending it.

🚨New Paper🚨 We explored pharmacological and extra-pharmacological predictors of the #psychedelic #LSD experience!Dose is key! Personality traits, mood, and pre-drug states are also major influencers! Sex and body weight? Not so much! Patrick Vizeli nature.com/articles/s4139…

In our latest paper, we emphasize the need for quantitative summaries of adverse events data to complement anecdotes and drive discourse on the risks and benefits of psychedelic research.

These findings are from a study in nature which used state-of-the-art precision functional mapping tools to delineate topology of functional brain networks in individuals with depression. nature.com/articles/s4158… 2/12

Great to see. Congrats to the PIs. news-medical.net/news/20240827/…

It’s hardly changed

Exactly as I remember it

“Panta Rhei [everything flows].” Heraclitus. 535–475 BCE.